Ionis – $500.3 Million Public Offering of Common Stock

San Diego – September 11, 2024 – Cooley advised Ionis Pharmaceuticals (Nasdaq: IONS), a biotechnology research company inventing medicines that bring better futures to people with serious diseases, on its $500.3 million underwritten public offering of common stock. Ionis issued and sold 11,500,000 shares of common stock priced at $43.50 per share, with a 30-day option for the underwriters to purchase up to an additional 1,725,000 shares. The offering closed on September 11, 2024. Morgan Stanley and Goldman Sachs acted as joint book-running managers for the offering.

Lawyers Charlie Kim, Natalie Karam, Nicholaus Johnson, Jayden Martinez and Allie Pilmer led the Cooley team advising Ionis.

Cooley previously advised Ionis on its $575 million convertible senior notes offering in June 2023 and its $1.1 billion royalty sale to Royalty Pharma in January 2023 (consisting of a $500 million upfront payment and up to $625 million in milestones).

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.